- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04341857
PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
August 23, 2021 updated by: Henan Cancer Hospital
Phase II Clinical Study of PD-1 Monoclonal Antibody (Sintilimab) Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma/ Esophagogastric Junction Adenocarcinoma
This is a prospective single arm phase II clinical study to compare the safety and efficacy of PD-1monoclonal antibody +FLOT in patients with gastric adenocarcinoma/esophagus-gastric junction adenocarcinoma.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Into a set of 25 cases of the gastric carcinoma confirmed by pathology or gastroesophageal junction adenocarcinoma (cT4 and/or N + M0, Multi-Disciplinary Team thought line to perioperative treatment) patients, preoperative accept four cycle by bead a resistance + sintilimab + capecitabine plus oxaliplatin into new adjuvant chemotherapy, because PD1 antibodies distance between surgery time interval is the lack of clinical data, judging by the researchers is 4 cycles of chemotherapy combination of sintilimab .The patient was able to undergo D2 radical surgery.Pathological examination was carried out to observe the pCR and the infiltration rate of immune cells.After the operation, patients continued to receive 4 cycles of capecitabine + oxaliplatin adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.Disease-free survival time and safety of treatment were observed, and OS, ORR and quality of life of all patients were followed up.
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Ding, MD
- Phone Number: 13526501903
- Email: lining97@126.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent has been signed;
- Only patients aged 18-75 were enrolled;
- Pathologically confirmed gastric adenocarcinoma (cT4 or/and N+M0, MDT considers perioperative treatment necessary) :Bone scan should be performed if bone metastasis is suspected.If peritoneal metastasis is suspected, laparoscopy should be performed;
- No previous cytotoxic chemotherapy or targeted therapy;
- No previous local resection of the tumor;
- ECOG 1 or less;
- Tumor specimens capable of detecting PDL-1 and MSI status are available.The detection of PDL-1 and MSI will be conducted after random grouping.This test requires the patient to provide a paraffin-embedded biopsy specimen;
- Leukocyte ≥ 4×109/L, platelet ≥ 100×109/L without transfusion, absolute value of neutrophils (ANC) without granulocyte stimulation factor ≥ 1.5×109/L, and hemoglobin≥ 90 g/L;
- Bilirubin ≤ 1.5 times of the upper limit of normal value, and rice grass and rice propyl transaminase ≤ 2.5 times of the upper limit of normal value;
- Serum creatinine ≤ 1.5 times the upper limit of normal value, or GFR>45ml/min;
- Serum albumin ≥ 25g /L (2.5g /dL);
- INR or aPTT ≤1.5 times ULN;
Exclusion Criteria:
- Allergy to any experimental drug and its excipients, or a history of severe allergy, or a contraindication to the experimental drug;
- Ahistory of autoimmune diseases or active stage;
- Previous allogeneic bone marrow transplantation or organ transplantation;
- Congenital pulmonary fibrosis, drug-induced pneumonia, organized pneumonia, or ct-confirmed active pneumonia;
- HIV test positive;
- Active hepatitis b or c;
- Active tuberculosis;
- Uncontrolled cancer pain;
- Live attenuated vaccine was injected within 4 weeks before the study began, or live attenuated vaccine was expected to be injected during the trial or within 5 months after the trial;
- Previous immunotherapy, including CTLA4, anti-pd-1, or anti-pdl1 monoclonal antibody;
- CT suggested active pulmonary inflammation;
- Systemic application of glucocorticoids or immunosuppressants within 2 weeks before the start of the trial.Inhaled glucocorticoids and glucocorticoids are allowed;
- There are taboos on hormone use;
- Severe cardiovascular disease, myocardial infection or cerebrovascular accident, arrhythmia, unstable angina within 3 months before the start of the trial;
- Uncontrolled increase in blood pressure or blood sugar;
- Other malignancies prior to 5 years, with the exception of cervical carcinoma in situ, non-melanoma skin cancer, or stage I uterine cancer;
- Known central nervous system metastases;
- Peripheral neuropathy ≥ NCI CTCAE grade 2;
- Serum albumin below 2.5 g/dL;
- Uncontrolled or symptomatic hypercalcemia;
- Infections requiring antibiotics within 14 days prior to the start of the trial;
- Chronic enteritis;
- Clinically significant active gastrointestinal bleeding;
- Non-diagnostic surgery within 4 weeks before the start of the trial;
- Any other disease where there is evidence of a need to restrict the use of the experimental drug;
- Participate in other tests within 30 days before the start of the test, or plan to participate in other tests during the test;
- Receive other experimental drugs within 28 days prior to the start of the trial;
- Pregnantor lactating women, or women who plan to become pregnant within 5months after the end of treatment.Women of childbearing age should undergo a blood pregnancy test within 7 days of the start of the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sintilimab combined with FLOT regimen
Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
|
Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response (pCR) rate
Time Frame: immediately after surgery
|
Complete pathological response can be determined if no tumor lesion remains or only carcinoma in situ remains in the Complete pathological response can be determined if no tumor lesion remains or only carcinoma in situ remains in the Complete pathological response can be determined if no tumor lesion remains or only carcinoma in situ remains in the surgical specimens (see WHO solid tumor efficacy criteria
|
immediately after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival(DFS)
Time Frame: From the date of first treatment dose until documented disease progression or death from any cause. whichever occur first, assessed up to 30 months
|
The interval between the dates of the first dose of trial treatment until first documentation of disease progression or death, whichever occurs first.
Patients with new non-breast cancer malignancy must continue to be followed for progression of the original breast cancer.
For patients without progression, follow-up is censored at the date of last disease assessment without progression, unless death occurs within 12 weeks following the date last known progression-free, in which case the death will be counted as a DFS event.
|
From the date of first treatment dose until documented disease progression or death from any cause. whichever occur first, assessed up to 30 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 30, 2019
Primary Completion (ANTICIPATED)
May 30, 2022
Study Completion (ANTICIPATED)
July 30, 2022
Study Registration Dates
First Submitted
April 1, 2020
First Submitted That Met QC Criteria
April 9, 2020
First Posted (ACTUAL)
April 10, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 24, 2021
Last Update Submitted That Met QC Criteria
August 23, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HN20190929
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric and Esophagogastric Junction Adenocarcinoma
-
Peking UniversityRecruitingProximal Gastric Adenocarcinoma | Anastomosis | Adenocarcinoma of Esophagogastric JunctionChina
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingGastric or Esophagogastric Junction Adenocarcinoma
-
Fujian Cancer HospitalWithdrawnGastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction AdenocarcinomaChina
-
Fujian Cancer HospitalUnknownAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric JunctionChina
-
Fujian Cancer HospitalUnknownAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric JunctionChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingGastric or Esophagogastric Junction AdenocarcinomaChina
-
Fudan UniversityRecruitingGastric Cancer/Adenocarcinoma of Esophagogastric JunctionChina
-
European Organisation for Research and Treatment...Active, not recruitingGastric and Esophagogastric Junction AdenocarcinomaUnited Kingdom, Italy, France, Spain, Germany, Czechia, Israel, Norway, Poland
-
AIO-Studien-gGmbHNeovii BiotechCompletedGastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisGermany
-
Krankenhaus NordwestCompletedGastric Cancer | Adenocarcinoma of the Esophagogastric JunctionGermany
Clinical Trials on PD-1 Monoclonal Antibody(Sintilimab)
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic SarcomaUnited States
-
Henlix, IncUnknown
-
Cancer Hospital of Guangxi Medical UniversityRecruitingNasopharyngeal Carcinoma | SintilimabChina
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
The First Affiliated Hospital of Guangzhou Medical...UnknownMultiple Primary Lung CancersChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
Sun Yat-sen UniversityNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Guangzhou Gloria Biosciences Co., Ltd.CompletedAdvanced Solid TumorsChina